Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPA | P38571 | 8/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NEK2 | P51955 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18282564 | 0.80 | LIPA (0.37) | LIPAALDH1A1HTTNPSR1KDM4E | |
| SCHEMBL4314831 | 0.79 | HTR1A (0.41) | LIPAALDH1A1HTTNPSR1KDM4E | |
| SCHEMBL18282589 | 0.77 | LIPA (0.37) | LIPAALDH1A1HTTNPSR1KDM4E | |
| SCHEMBL18282665 | 0.75 | ALDH1A1 (0.38) | LIPAALDH1A1HTTKDM4EMAPT | |
| SCHEMBL20423495 | 0.75 | ALDH1A1 (0.34) | LIPAALDH1A1HTTNPSR1HSD17B10 | |
| SCHEMBL18282613 | 0.74 | LIPA (0.33) | LIPAALDH1A1HTTNPSR1KDM4E | |
| SCHEMBL18282570 | 0.74 | ALDH1A1 (0.40) | LIPAALDH1A1HTTNPSR1KDM4E | |
| SCHEMBL18282487 | 0.73 | ALDH1A1 (0.35) | LIPAALDH1A1HTTNPSR1KDM4E | |
| SCHEMBL18282555 | 0.73 | LIPA (0.35) | LIPAALDH1A1HTTNPSR1KDM4E | |
| SCHEMBL18282553 | 0.72 | LIPA (0.32) | LIPAALDH1A1KDM4EMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774074-B2 | 2-(1-heteroarylpiperazin-4-yl)methyl-1,4-benzodioxane derivatives as alpha2C antagonists | ORION CORPORATION (FI) | 2020-09-15 | — | — | US | disclosed |
| EP-3303327-B1 | 2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS | ORION CORP (FI) | 2020-03-11 | — | — | EP | disclosed |
| US-20190292170-A9 | 2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS | ORION CORPORATION (FI) | 2019-09-26 | — | — | US | disclosed |
| US-20180215739-A1 | 2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS | ORION CORPORATION (FI) | 2018-08-02 | — | — | US | disclosed |
| EP-3303327-A1 | 2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS | Orion Corporation (FI) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016193551-A1 | 2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS | ORION CORPORATION (FI) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215739-A1 | 2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS | OPRM1, HTR2C, ADRA2C | LIPA 4869/4885ALDH1A1 972/4885HTT 3395/4885 |
| US-10774074-B2 | 2-(1-heteroarylpiperazin-4-yl)methyl-1,4-benzodioxane derivatives as alpha2C antagonists | OPRM1, HTR2C, ADRA2C | LIPA 4869/4885ALDH1A1 972/4885HTT 3395/4885 |
| US-20190292170-A9 | 2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS | OPRM1, HTR2C, ADRA2C | LIPA 4869/4885ALDH1A1 972/4885HTT 3395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.